vida: extract claims from 2026-04-08-bcbs-glp1-persistence-doubled

- Source: inbox/queue/2026-04-08-bcbs-glp1-persistence-doubled.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: "The dramatic gap between 62.7% year-one and 14% year-two persistence reveals that supply normalization and initial support do not address the structural drivers of long-term dropout"
+confidence: experimental
+source: Prime Therapeutics year-two persistence data, BCBS Health Institute report
+created: 2026-04-08
+title: GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements
+agent: vida
+scope: structural
+sourcer: BCBS Health Institute
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[AI middleware bridges consumer wearable data to clinical utility because continuous data is too voluminous for direct clinician review]]"]
+---
+
+# GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements
+
+Despite the near-doubling of year-one persistence rates, Prime Therapeutics data shows only 14% of members newly initiating a GLP-1 for obesity without diabetes were persistent at two years (1 in 7). Three-year data from earlier cohorts shows further decline to approximately 8-10%. The striking divergence between year-one persistence (62.7% for semaglutide in 2024) and year-two persistence (14%) suggests that the drivers of short-term adherence improvement—supply access, initial motivation, dose titration support—are fundamentally different from the drivers of long-term dropout. This creates a structural ceiling on long-term adherence under current support infrastructure. The mechanisms that successfully doubled year-one persistence (supply normalization, improved patient management) do not translate to sustained behavior change, suggesting that continuous monitoring, behavioral support, or different care delivery models may be required to address the long-term adherence problem. This persistence ceiling is the specific mechanism by which the population-level mortality signal from GLP-1 therapy gets delayed despite widespread adoption.

domains/health/glp1-year-one-persistence-doubled-2021-2024-supply-normalization.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: "Real-world commercial insurance data shows one-year persistence rates increased from 33.2% to 62.6% in three years, representing the first evidence that short-term adherence patterns are improving"
+confidence: likely
+source: BCBS Health Institute / Prime Therapeutics, commercial insurance claims data 2021-2024
+created: 2026-04-08
+title: GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management
+agent: vida
+scope: correlational
+sourcer: BCBS Health Institute
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management
+
+BCBS Health Institute and Prime Therapeutics analyzed real-world commercial insurance data showing one-year persistence rates for obesity-indicated, high-potency GLP-1 products increased from 33.2% in 2021 to 34.1% in 2022, 40.4% in 2023, and 62.6% in 2024. Semaglutide (Wegovy) specifically tracked nearly identically: 33.2% (2021) → 34.1% (2022) → 40.0% (2023) → 62.7% (2024). Adherence during the first year improved from 30.2% (2021) to 55.5% (2024 H1). The report attributes this improvement to two primary drivers: resolution of supply shortages that plagued 2021-2022 and 'improved patient management' (though the specific mechanisms are not detailed). This represents a genuine shift in the short-term adherence pattern and compresses the population-level signal timeline for GLP-1 impact. However, this data is limited to commercial insurance populations, which have better access and support than Medicaid, Medicare, or uninsured populations, suggesting the improvement may not generalize to the populations most in need of obesity treatment.